South Korea
· Delayed Price · Currency is KRW Sam Chun Dang Pharm. Statistics
Total Valuation
Sam Chun Dang Pharm. has a market cap or net worth of KRW 3.30 trillion. The enterprise value is 3.30 trillion.
| Market Cap | 3.30T |
| Enterprise Value | 3.30T |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Sam Chun Dang Pharm. has 23.26 million shares outstanding. The number of shares has increased by 3.20% in one year.
| Shares Outstanding | 23.26M |
| Shares Change (YoY) | +3.20% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 6.98% |
| Owned by Institutions (%) | 9.66% |
| Float | 14.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.80 |
| PB Ratio | 11.92 |
| P/FCF Ratio | 123.04 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 195.60, with an EV/FCF ratio of 123.11.
| EV / Earnings | -589.72 |
| EV / Sales | 16.14 |
| EV / EBITDA | 195.60 |
| EV / EBIT | n/a |
| EV / FCF | 123.11 |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.15.
| Current Ratio | 3.31 |
| Quick Ratio | 2.76 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 3.20 |
| Debt / FCF | 2.02 |
| Interest Coverage | 6.37 |
Financial Efficiency
Return on equity (ROE) is 0.23% and return on invested capital (ROIC) is 1.37%.
| Return on Equity (ROE) | 0.23% |
| Return on Assets (ROA) | 1.17% |
| Return on Capital (ROIC) | 1.37% |
| Revenue Per Employee | 510.70M |
| Profits Per Employee | -13.98M |
| Employee Count | 400 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 2.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +88.64% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +88.64% |
| 50-Day Moving Average | 150,572.00 |
| 200-Day Moving Average | 117,987.00 |
| Relative Strength Index (RSI) | 53.12 |
| Average Volume (20 Days) | 480,610 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sam Chun Dang Pharm. had revenue of KRW 204.28 billion and -5.59 billion in losses. Loss per share was -245.53.
| Revenue | 204.28B |
| Gross Profit | 98.88B |
| Operating Income | 8.39B |
| Pretax Income | 2.41B |
| Net Income | -5.59B |
| EBITDA | 16.86B |
| EBIT | 8.39B |
| Loss Per Share | -245.53 |
Balance Sheet
The company has 132.05 billion in cash and 54.01 billion in debt, giving a net cash position of 78.04 billion or 3,355.46 per share.
| Cash & Cash Equivalents | 132.05B |
| Total Debt | 54.01B |
| Net Cash | 78.04B |
| Net Cash Per Share | 3,355.46 |
| Equity (Book Value) | 356.50B |
| Book Value Per Share | 11,890.80 |
| Working Capital | 171.32B |
Cash Flow
In the last 12 months, operating cash flow was 35.29 billion and capital expenditures -8.51 billion, giving a free cash flow of 26.78 billion.
| Operating Cash Flow | 35.29B |
| Capital Expenditures | -8.51B |
| Free Cash Flow | 26.78B |
| FCF Per Share | 1,151.65 |
Margins
Gross margin is 48.40%, with operating and profit margins of 4.11% and -2.74%.
| Gross Margin | 48.40% |
| Operating Margin | 4.11% |
| Pretax Margin | 1.18% |
| Profit Margin | -2.74% |
| EBITDA Margin | 8.25% |
| EBIT Margin | 4.11% |
| FCF Margin | 13.11% |
Dividends & Yields
Sam Chun Dang Pharm. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.20% |
| Shareholder Yield | -3.20% |
| Earnings Yield | -0.17% |
| FCF Yield | 0.81% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sam Chun Dang Pharm. has an Altman Z-Score of 9.67.
| Altman Z-Score | 9.67 |
| Piotroski F-Score | n/a |